Alchemab Therapeutics raised £25M in a Series A round announced on July 9, 2026. Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics, based in London, United Kingdom, announced £25M in Series A financing on July 9, 2026.
Participants include British Business Bank.
Humanoid is a UK-based AI and robotics company building industrial humanoid robots.
Valarian delivers advanced data sovereignty infrastructure engineered to empower commercial enterprises and government institutions with full data ownership.